Vigil Neuroscience reports Q3 EPS (53c), consensus (57c)

“We continue to make significant progress in advancing our novel TREM2 agonist candidates – VGL101 in ALSP and VG-3927 in Alzheimer’s disease, and believe we are well-positioned to become a leader in neurodegenerative drug development,” said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “Importantly, we are diligently advancing our Phase 2 IGNITE trial, the first interventional study in ALSP, and expect to report our interim results from the first six patients treated for six months with VGL101 this quarter. In September, we also proudly introduced our oral small molecule TREM2 agonist candidate, VG-3927, with the opening of our IND. We dosed our first participant in our Phase 1 clinical trial in healthy volunteers last month and expect to share interim results in mid-2024.”